We will use the BPD mouse model to test the therapeutic potential of Wnt ligands and other factors produced by Lgr5-expressing mesenchymal cells. Our ability to model alveolar differentiation in organoids provides a whole new way to understand and treat BPD. The molecules we identify could one day be administered to prevent or alleviate the lung developmental abnormalities in BPD patients.